Actively Recruiting
Long-Term Safety Follow-Up of Participants Treated with Azer-Cel, an Allogeneic CAR T-Cell Therapy, in a TG Therapeutics Clinical Study
Led by TG Therapeutics, Inc. · Updated on 2026-10-29
32
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to collect long-term safety data on azer-cel, an allogeneic chimeric antigen receptor T-cell product, in participants with B-cell mediated autoimmune disorders. The study will primarily focus on tracking clinical events of interest over a period of up to 15 years following prior participation in the TG-Azercel -101 study. The goal is to better understand the long-term safety profile of this therapy. Participants who have previously received azer-cel in the TG-Azercel -101 study will be monitored without receiving any new intervention. The follow-up period extends up to 15 years or until participants withdraw consent, are lost to follow-up, or pass away. This observational study involves no additional treatment but focuses on gathering safety information during this extended period. During the follow-up, participants will be regularly assessed for clinically significant clinical events of interest, including their severity, duration, and time to onset. Other measures include the monitoring of serious adverse events, disease response duration using disability scales, relapse counts, and MRI lesion assessments. This extensive observation aims to provide comprehensive long-term safety information over many years.
CONDITIONS
Brief Title
Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel
Research Team
T
TG Therapeutics Clinical Support Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here